Table 4.
Variable | Anti-Jo1+ Patients n: 10 |
Anti-PL7+ Patients n: 8 |
Anti-PL12+ Patients n: 11 |
Anti-EJ+ Patients n: 10 |
p-Value | ILD anti tRNA Positive Patients n: 39 |
---|---|---|---|---|---|---|
IL-1β | 92 (75.3–310) | 202 (65–327) | 319 (107–335) | 239 (105–318) | 0.22 | 264 (88–324) |
IL-2 | 262 (236–284) | 280 (214–286) | 278 (273–282) | 279 (272–284) | 0.82 | 278 (247–284) |
IL-4 | 288 (277–624) | 522 (261–761) | 730 (446–786) | 695 (516–744) | 0.09 | 688 (283–758) |
IL-5 | 408 (308–458) | 354 (226–465) | 453 (370–459) | 453 (440–463) | 0.79 | 452 (311–463) |
IL-6 | 445 (423–2243) | 1509 (437–2283) | 2205 (415–2318) | 1996 (440–2324) | 0.67 | 1694 (438–2313) |
IL-9 | 454 (383–495) | 430 (389–524) | 434 (412–480) | 463 (450–565) | 0.71 | 454 (412–495) |
IL-10 | 70 (67–73) | 73 (48–85) | 74 (71–97) | 76 (70–84) | 0.31 | 73 (68–81) |
IL-12 p70 | 321 (287–331) | 317 (289–324) | 302 (290–318) | 305 (279–326) | 0.88 | 311 (287–326) |
IL-13 | 105 (95–124) | 144 (108–189) | 153 (117–167) | 123 (106–190) | 0.21 | 119 (104–174) |
IL-17A | 232 (167–290) | 230 (146–290) | 193 (151–290) | 214 (176–289) | 0.89 | 201 (164–289) |
IL-18 | 908 (795–1408) | 907 (814–1170) | 1065 (1022–1292) | 1037 (966–1441) | 0.23 | 1022 (875–1353) |
IL-21 | 283 (175–379) | 349 (259–505) | 340 (273–358) | 345 (294–564) | 0.64 | 346 (233–450) |
IL-22 | 871 (740–952) | 1026 (730–1064) | 1027 (981–1058) | 1017 (883–1048) | 0.37 | 1017 (824–1058) |
IL-23 | 898 (863–947) | 917 (795–979) | 937 (916–1003) | 932 (903–1259) | 0.28 | 927 (885–976) |
IL-27 | 453 (447–469) * | 474 (458–483) | 474 (464–492) | 483 (264–324) * | 0.02 | 473 (458–485) |
INF-γ | 661 (624–724) | 698 (607–950) | 815 (633–938) | 819 (668–856) | 0.41 | 720 (644–860) |
GM-CSF | 856 (725–856) | 808 (667–856) | 843 (688–856) | 686 (662–856) | 0.77 | 843 (670–856) |
TNF-α | 346 (326–405) | 365 (313–404) | 405 (403–407) | 403 (349–404) | 0.07 | 403 (332–405) |
The units of the serum cytokine concentrations were pg/mL in all cases. All values are expressed as medians (IQR). * Patients positive for anti-Jo1 and anti-EJ showed statistically significant differences after having performed the Bonferroni correction.